634-65-1

Basic information

• Product Name: 2,4-DIMETHYL-1,3-BENZENEDIOL
• Synonyms: 2,4-DIMETHYL-1,3-BENZENEDIOL;2,4-dimethylbenzene-1,3-diol;1,3-Dihydroxy-2,4-dimethylbenzene;2,4-Dimethyl-1,3-dihydroxybenzene;2,6-DiMethyl-1,3-benzenediol;m-Xylene-2,4-diol
• CAS NO: 634-65-1
• Molecular Formula: C₈H₁₀O₂
• Molecular Weight: 138.16
• EINECS: 211-213-5
• Product Categories: API intermediates
• Mol File: 634-65-1.mol

Chemical Properties

• Melting Point: 110℃
• Boiling Point: 286℃
• Flash Point: 142℃
• Appearance: /
• Density: 1.162
• Vapor Pressure: 0.00153mmHg at 25°C
• Refractive Index: 1.582
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 10.42±0.23(Predicted)
• CAS DataBase Reference: 2,4-DIMETHYL-1,3-BENZENEDIOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DIMETHYL-1,3-BENZENEDIOL(634-65-1)
• EPA Substance Registry System: 2,4-DIMETHYL-1,3-BENZENEDIOL(634-65-1)

Safety Data

• Hazardous Substances Data: 634-65-1(Hazardous Substances Data)

Usage

Purification Methods

Crystallise the resorcinol from pet ether (b 60-80o), *C6H6/pet ether or toluene/BuOAc. It sublimes at 100-110o/1mm. [Beilstein 6 H 918, 6 II 891, 6 III 4588, 6 IV 5955.]

InChI:InChI=1/C8H10O2/c1-5-3-4-7(9)6(2)8(5)10/h3-4,9-10H,1-2H3

Upstream product

• 6248-20-0 2,4-dihydroxy-3-methylbenzaldehyde 
• 3328-71-0 2,4-dihydroxyisophthalic anhydride 
• 85705-31-3 3,5-Dimethyl-2,4-dioxo-1-cyclohexancarbonsaeure-methylester 
• 89980-91-6 5-bromo-2,4-dimethyl-resorcinol 
• 58661-08-8 6-hydroxy-5,6-dimethyl-cyclohexa-2,4-dienone 
• 108-24-7 acetic anhydride 
• 108-46-3 recorcinol 
• 49582-92-5 1,3-diacetoxy-2,4-dimethyl-benzene 
• 91721-05-0 5-Brom-2,4-dimethyl-resorcin-diacetat 
• 608-25-3 2-methylbenzene-1,3-diol 
• 105-67-9 2,4-Xylenol 
• 576-26-1 2.6-dimethylphenol 

Downstream Products

• 88924-67-8 2,4-dimethyl-6-hexanoyl-resorcinol 
• 89980-91-6 5-bromo-2,4-dimethyl-resorcinol 
• 412022-03-8 2-chloro-1-(2,4-dihydroxy-3,5-dimethyl-phenyl)-ethanone 
• 20935-62-0 1,3-dimethoxy-2,4-dimethylbenzene 
• 577-45-7 1-(2,4-dihydroxy-3,5-dimethylphenyl)ethanone 
• 79950-85-9 sorbicillin 
• 90536-32-6 2,4-dihydroxy-3,5-dimethylbenzaldehyde 
• 90536-63-3 2,4-dihydroxy-3,5-dimethylbenzoic acid 
• 251091-29-9 (+/-)-6-acetoxy-4-(2,4-hexadienoyl)-3-hydroxy-2,6-dimethyl-2,4-cyclohexadien-1-one 
• 267001-61-6 methyl 2,4-dihydroxy-3,5-dimethylbenzoate 
• 267001-71-8 2,4-dimethyl-6-isobutyryl-resorcinol 
• 267001-77-4 2,6-dimethyl-6-acetoxy-4-acetyl-3-hydroxy-2,4-cyclohexadien-1-one 

Relevant articles and documents

Synthesis of sorbicillinoid analogues with anti-inflammation activities

Recently, we demonstrated potential anti-inflammatory effects of sorbicillinoids isolated from marine fungi. Here, we report the synthesis of a series of new sorbicillinoid analogues and assessed their anti-inflammatory activities. Our results reveal that side chain substitution with (E)-2-butenoyl, (E)-3-(4-fluorophenyl)-2-propenoyl, and (E)-3-(3,4,5-trimethoxyphenyl)-2-propenoyl significantly enhanced the inhibitory effects of the derivatives on nitric oxide (NO) production and inducible NO synthesis (iNOS) expression stimulated by lipopolysaccharides (LPS) in mouse macrophage. Further chemical derivatization shows that the monomethylresorcinol skeleton worked better than the dimethylresorcinol skeleton in inhibiting LPS-induced inflammatory response in cultured cells. Among the 29 synthesized sorbicillinoid analogues, compounds 4b and 12b exhibited the strongest anti-inflammatory activities, holding the promise of being developed into lead compounds that can be explored as potent anti-inflammation agents.

Syntheses of the Carotane-type Terpenoids (+)-Schisanwilsonene A and (+)-Tormesol via a Two-Stage Approach

Stereoselective syntheses of terpenoids in a more efficient manner have been a long-term pursuit for synthetic chemists. Herein we describe the two-step, enantiospecific and protecting-group-free synthesis of (+)-schisanwilsonene A from a carotane compound, which was produced in E. coli. We also completed the first enantiomeric synthesis of (+)-tormesol in five steps. The two-stage strategy offers a step- and redox-economical approach to prepare terpene natural products and their analogues.

Bypassing Biocatalytic Substrate Limitations in Oxidative Dearomatization Reactions by Transient Substrate Mimicking

Enzymatic oxidative dearomatization is an efficient way to generate chiral molecules from simple arenes. One example is the flavin-dependent monooxygenase SorbC involved in sorbicillinoid biosynthesis. However, SorbC requires a long-chain keto substituent at its phenolic substrate, thus preventing its application beyond the synthesis of natural sorbicillinoids or close structural analogues. This work describes an approach to broaden the accessible product spectrum of SorbC by employing an ester functionality mimicking the natural substrate structure during enzymatic oxidation.

Stereoselective Total Synthesis of Bisorbicillinoid Natural Products by Enzymatic Oxidative Dearomatization/Dimerization

Natural products are a virtually inexhaustible source of small molecules with spectacular molecular architectures and biomedical potential. Their structural complexity generates formidable challenges to total synthesis but often also precludes time- and resource-efficient, stereoselective synthetic access. Biosynthetically, nature frequently uses dimerization and oligomerization reactions to produce highly challenging frameworks from simple starting materials. Impressive examples are the bisorbicillinoids, a family of fungal natural products thought to originate from the polyketide precursor sorbicillin. Utilizing the recombinant oxidoreductase SorbC from the sorbicillin biosynthetic gene cluster, a robust, fully stereoselective synthesis of bisorbicillinoid natural products and unnatural side-chain analogues was developed.

FLUORESCENT PROBES FOR DETECTION OF COPPER

The invention provides fluorescent sensors for the selective detection of a metal such as copper. The sensors may be considered to be derivatives of cyanine, fluorescein, rhodamine, rhodol, Tokyo green, or BODIPY. The sensors find particular use in detecting copper in cells and living animals.

PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS

The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.

Polymer electrolyte and process for producing the same

A polymer electrolyte having, in a main chain, a structural unit represented by the following formula (1):-[Ar1-(SO2-N-(X+)-SO2-Ar2)m-SO2-N-(X+)-SO2-Ar1-O]- wherein Ar1 and Ar2 independently represent a divalent aromatic groups, m represents an integer of 0 to 3, and X+ represents an ion selected from hydrogen ion, an alkali metal ion and ammonium ion, which is excellent in proton conductivity, thermal resistance and strength. The polymer electrolyte is soluble in solvents and has excellent film forming property and recycling efficiency.

COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS

This invention relates to a method of treating Parkinson's Disease whereby a mammal suffering from Parkinson's Disease is treated with a combination of a forebrain selective NMDA antagonist and a compound which is capable of increasing the excitatory feedback from the ventral lateral nucleus of the thalamus into the cortex. This invention also relates to pharmaceutical compositions containing the synergistic combination.

Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives

PCT No. PCT/IB95/00380 Sec. 371 Date Feb. 13, 1996 Sec. 102(e) Date Feb. 13, 1996 PCT Filed May 18, 1995 PCT Pub. No. WO96/06081 PCT Pub. Date Feb. 29, 1996This invention relates to compounds of formula (I), or pharmaceutically acceptable acid addition salts thereof, wherein: (a) R2 and R5 are taken separately and R1, R2, R3 and R4 are each independently hydrogen, (C1-C6) alkyl, halo, CF3, OH or OR7 and R5 is methyl or ethyl; or (b) R2 and R5 are taken together, forming a chroman-4-ol ring, and R1, R3 and R4 are each independently hydrogen, (C1-C6) alkyl, halo, CF3, OH or OR7; and R6 is a substituted piperidinyl, pyrrolidinyl or 8-azabicyclo(3.2.1)octanyl derivative; provided that (a) when R2 and R5 are taken separately, at least one of R1, R2, R3 and R4 is not hydrogen; and (b) when R2 and R5 are taken together, at least one of R1, R3 and R4 is not hydrogen; pharmaceutical compositions thereof; and methods of treating mammals suffering from stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, CNS degenerative diseases such as Alzheimer's disease, senile dementia of the Alzheimer's type, Huntington's disease, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, pain, AIDS dementia, psychotic conditions, drug addictions, migraine, hypoglycemia, anxiolytic conditions, urinary incontinence and an ischemic event arising from CNS surgery, open heart surgery or any procedure during which the function of the cardiovascular system is compromised with a compound of formula (I) hereinabove or a pharmaceutically acceptable salt thereof.